XML 44 R18.htm IDEA: XBRL DOCUMENT

Investments in Non-Publicly Traded Companies	3 Months Ended
Mar. 31, 2013
Investments, All Other Investments [Abstract]
Cost-method Investments, Description [Text Block]	Note 12. Investments in Non-Publicly Traded Companies The Company owns a 3% limited partnership interest in Neurone II, a venture capital fund organized as a limited partnership and a 0.42% limited partnership interest in Munich Venture Partners Fund. The Company accounts for these investments at cost. The financial condition of these partnerships is subject to significant changes resulting from their operating performance and their ability to obtain financing. The Company continually evaluates its investments in these companies for impairment. In making this judgment, the Company considers the investee’s cash position, projected cash flows (both short-term and long-term), financing needs, most recent valuation data, the current investing environment, management/ownership changes, and competition. This evaluation process is based on information that the Company requests from these privately held companies. This information is not subject to the same disclosure and audit requirements as the reports required of U.S. public companies, and as such, the reliability and accuracy of the data may vary. For the three months ended March 31, 2013 and 2012, there were no impairment charges related to the Company’s investments in non-publicly traded companies. The Company made an additional investment of less than $0.1 million during the three months ended March 31, 2012.

Investments in Non-Publicly Traded Companies

3 Months Ended

Mar. 31, 2013

Investments, All Other Investments [Abstract]

Cost-method Investments, Description [Text Block]

Note 12. Investments in Non-Publicly Traded Companies

The Company owns a 3% limited partnership interest in Neurone II, a venture capital fund organized as a limited partnership and a 0.42% limited partnership interest in Munich Venture Partners Fund. The Company accounts for these investments at cost. The financial condition of these partnerships is subject to significant changes resulting from their operating performance and their ability to obtain financing. The Company continually evaluates its investments in these companies for impairment. In making this judgment, the Company considers the investee’s cash position, projected cash flows (both short-term and long-term), financing needs, most recent valuation data, the current investing environment, management/ownership changes, and competition. This evaluation process is based on information that the Company requests from these privately held companies. This information is not subject to the same disclosure and audit requirements as the reports required of U.S. public companies, and as such, the reliability and accuracy of the data may vary.

For the three months ended March 31, 2013 and 2012, there were no impairment charges related to the Company’s investments in non-publicly traded companies. The Company made an additional investment of less than $0.1 million during the three months ended March 31, 2012.

- Definition

The entire disclosure for investments accounted for under the cost-method. The carrying amount of such investments may be adjusted, for example, distributions in excess of cost (return of capital) or for other-than-temporary impairments. The cost method and lower-of-cost or market, an adaptation of the cost method, is generally followed for most investments in noncontrolled corporations, in some corporate joint ventures, and to a lesser extent in unconsolidated subsidiaries in which the entity does not have the ability to exercise significant influence.

+ References+ Details